Caris Life Sciences vs Visiopharm

Visiopharm is software a pathology lab runs on its own scanned slides, and Caris is a tissue-sequencing service an oncologist orders. For a lab in the EU or UK the Visiopharm side is concrete: CE-IVD apps for ER, PR, HER2 and Ki-67, with nine diagnostic algorithms cleared under IVDR, the vendor says. Grundium Oy announced its acquisition of Visiopharm A/S on May 21, 2026, terms undisclosed. In the US the homepage labels products research use only unless otherwise stated, and an openFDA 510(k) search under the company name returned no match on October 14, 2026.

Caris sells MI Cancer Seek, PMA P240010, approved November 5, 2024, for FFPE tumor tissue. The MI Cancer Seek page gives a median turnaround of 8 days and also says 6 to 9. The vendor says orders integrate by EHR at 3,100+ locations and does not name the systems.